How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Endovenous Ablation Market
- By Product Type: Radiofrequency Ablation Devices, Laser Ablation Devices, Ultrasound Ablation Devices, Steam Ablation Devices, Sclerotherapy Agents
- By Procedure Type: Endovenous Laser Ablation (EVLA), Radiofrequency Ablation (RFA), Ultrasound-Guided Foam Sclerotherapy, Steam Vein Sclerosis (SVS)
- By Vein Type Treated: Great Saphenous Vein, Small Saphenous Vein, Perforator Veins, Varicose Veins
- By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Phlebology Clinics
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Radiofrequency Ablation Devices leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 14 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 272 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.164 →
- 11 Company Profiles 14 players: SWOT & benchmarking p.172 →
Full report · locked preview
Everything inside the Endovenous Ablation Market report
A complete, evidence-based study - 11 chapters and 114 sections covering market size, segmentation across 4 axes, regional analysis and 14 company profiles, forecast to 2033.
Segmentation covered
Product Type 5
Procedure Type 4
Vein Type Treated 4
End User 4
Companies profiled
Medtronic
Johnson & Johnson (Biosense Webster)
AngioDynamics
Venus Concept
Biolitec AG
Siemens Healthineers
Cook Medical
Terumo Corporation
BTG International (a Boston Scientific company)
Vascular Insights
Venclose
Venefit (a division of Medtronic)
+2 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
14 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Medtronic
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Johnson & Johnson (Biosense Webster)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →AngioDynamics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Venus Concept
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Biolitec AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Siemens Healthineers
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Cook Medical
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Terumo Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →BTG International (a Boston Scientific company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Vascular Insights
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Venclose
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Venefit (a division of Medtronic)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Venous Solutions
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Venous Technologies
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$1,616M by 2033 · 5.0% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Radiofrequency Ablation Devices39.1
- Laser Ablation Devices15.2
- Ultrasound Ablation Devices12.3
- Steam Ablation Devices16.4
- Sclerotherapy Agents17.0
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$361.7M → $526.7M · 4.8%
Europe$252.1M → $377.0M · 5.2%
Asia Pacific$230.2M → $359.0M · 5.7%
Latin America$142.5M → $216.8M · 5.4%
Middle East and Africa$109.6M → $151.5M · 4.1%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →4.932026
4.942027
4.942028
4.972029
4.972030
4.992031
4.992032
5.012033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Medtronic16.6
- Johnson & Johnson (Biosense Webster)10.5
- AngioDynamics13.6
- Venus Concept12.5
- Biolitec AG5.6
- Siemens Healthineers13.2
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type32.7%
Procedure Type12.2%
Vein Type Treated15.1%
End User40.0%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.3
- Europe23.1
- Asia Pacific22.0
- Latin America13.3
- Middle East and Africa9.3
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Medtronic | 76 | 90 | 95 | 94 | 93 | 78 | 88 |
| Johnson & Johnson (Biosense Webster) | 85 | 91 | 82 | 90 | 80 | 78 | 84 |
| AngioDynamics | 68 | 63 | 76 | 79 | 84 | 68 | 73 |
| Venus Concept | 61 | 69 | 62 | 58 | 75 | 60 | 64 |
| Biolitec AG | 56 | 62 | 68 | 67 | 68 | 72 | 66 |
| Siemens Healthineers | 53 | 46 | 53 | 50 | 70 | 57 | 55 |
| Cook Medical | 63 | 43 | 46 | 49 | 51 | 65 | 53 |
| Terumo Corporation | 52 | 50 | 58 | 48 | 45 | 39 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Medtronic
- Johnson & Johnson (Biosense Webster)
- AngioDynamics
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Medtronic | ◐ | ◐ | ✓ | ✓ | ✓ | ✓ |
| Johnson & Johnson (Biosense Webster) | ✓ | ✓ | ◐ | ✓ | ◐ | ◐ |
| AngioDynamics | ◐ | ◐ | ✓ | ◐ | ◐ | ◐ |
| Venus Concept | ◐ | ✓ | − | − | ✓ | ◐ |
| Biolitec AG | − | − | ✓ | ◐ | ◐ | − |
| Siemens Healthineers | ◐ | ◐ | − | − | ◐ | − |
| Cook Medical | ◐ | − | − | − | − | − |
| Terumo Corporation | − | − | ◐ | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Medtronic88
2Johnson & Johnson (Biosense Webster)84
3AngioDynamics73
4Biolitec AG66
5Venus Concept64
6Siemens Healthineers55
7Cook Medical53
8Terumo Corporation49
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
MedtronicJohnson & Johnson (Biosense Webster)
Challenger1
Strong scale, closing on the leaders.
AngioDynamics
Contender2
Focused players with pockets of strength.
Venus ConceptBiolitec AG
Niche3
Specialists in a single segment or region.
Siemens HealthineersCook MedicalTerumo Corporation
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Product Type in North America, then scale across Endovenous Ablation Market — a $182M beachhead inside a $3.04B market.
Beachhead (SOM)$182Mobtainable near-term
Serviceable (SAM)$1.12Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
Radiofrequency Ablation Devices
Best fit — highest urgency & budget in Product Type.
Economic buyer80 fit
Laser Ablation Devices
Strong fit — clear ROI and a fast path to value.
End user69 fit
Ultrasound Ablation Devices
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Procedure Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Vein Type Treated
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel31%
Digital / self-serve20%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Endovenous Ablation Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified22%
Evaluation12%
Closed-won6%
$12.5KCAC
$63KLTV
5.1:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Endovenous Ablation Market is a resilient opportunity — $2.70B by 2033, compounding at 3.3%.
TAM · 2025$2.08Btoday
TAM · 2033$2.70Bforecast
CAGR3.3%2027–2033
Cumulative$21.4Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$2.70BTotal addressable market
SAM$1.00BServiceable available market
SOM$203MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →3.3% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
14+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$2.70BLarge & growingTAM by 2033 at 3.3% CAGR
$1.00BServiceable nowreachable with today’s model
$203MBeachhead winobtainable near-term share
14+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.10BBear2.1% CAGR
$2.70BBase3.3% CAGR
$3.45BBull4.3% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Procedure Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Endovenous Ablation Market — a $1.95B market by 2033. Plan: grow share from 7.8% to 14.8%.
Market size · 2033$1.95Btotal addressable
Market CAGR11.6%2027–2033
Target share14.8%from 7.8% today
Revenue ambition$288Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.8% | 14.8% | Ahead |
| Revenue | $162M | $288M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 29.7% | 42.4% | On track |
| Customer retention | 89.9% | 95.1% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Procedure Type capability
A defensible second engine — invest in Procedure Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Procedure Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $33M capacity & capability investment
- Greenlight bolt-on M&A in Procedure Type
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskBehind
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Endovenous Ablation Market conversation — a $6.47B market you can size, segment and defend in minutes.
Market size · 2033$6.47Btotal opportunity
Growth7.7%CAGR to 2033
Addressable buyers1,490+accounts in scope
Typical ROI5.9×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.9×return on cost, year one
< 3 mopayback period
$88K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
14+players profiled in this market
Coverage includes
MedtronicJohnson & Johnson (Biosense Webster)AngioDynamicsVenus ConceptBiolitec AGSiemens HealthineersCook MedicalTerumo Corporation+6 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Endovenous Ablation Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Endovenous Ablation Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Endpoint Detection and Response (EDR) Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportEndpoint Security And Protection Softwarexa0 Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportENDRIN CAS 72-20-8 Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportEnd-suction Pump Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportEnd-to-End Aircraft Maintenance Software Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportEnd-to-end Email Encryption Market
Market size, share, segmentation and regional forecast.
$961M market · 2025 base year
View reportEnd-to-End Optical Beam Smoke Detector Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportEnd-use Mobile Work Platform Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportEnema Bags Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportEnema Machine Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportEnema Syringe Instrument Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportEnergetic Materials Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.